undamentalytics Newsletter
Sign in

Cocrystal Pharma, Inc. revenue

Cocrystal Pharma, Inc.'s revenue was $2.0m in fiscal 2020, down 69.3% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112019Dec 20192020Dec 2020
Revenue1372
Growth on the year before—−48.4%−69.3%
Gross profit3——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Cocrystal Pharma, Inc. $2.0m -69.3% —
Korsana Biosciences, Inc. $1.9m -12.6% —
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Collplant Biotechnologies Ltd $2.4m 360.4% —
Korro Bio, Inc. $2.4m -62.1% -53.7%
Vistagen Therapeutics, Inc. $2.5m 287.3% —

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cocrystal Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cocrystal Pharma, Inc.